Mitsubishi Tanabe Pharma America’s acceptance of a funding request is dependent upon multiple factors including, but not limited to, scientific merit, company goals, and availability of resources/funding.
Completed funding requests must be received at least 60 days prior to the program start date. This allows Mitsubishi Tanabe Pharma America to review each request thoroughly and answer any questions that applicants might have during the review process.
Once you submit your funding request application, you will receive the following automatic notifications from Mitsubishi Tanabe Pharma America:
We are currently receiving and reviewing grant funding requests for independent, objective, educational programs and activities that provide legitimate education of healthcare professionals and/or the public in the therapeutic areas of Amyotrophic Lateral Sclerosis (ALS). Currently, Mitsubishi Tanabe Pharma America, Inc. is not accepting any medical education grant requests for Parkinson's Disease, Erythropoietic Protoporphyria (EPP), and X-Linked Protoporphyria (XLP).
Grant requests may come from academic institutions, state or national medical associations or societies, disease foundations and associations, patient associations, or other educational providers. For academic institutions, the University Grants Office should apply for the grant, rather than an individual department or research group. Preference will be given to requests that are ACCME accredited, contain an educational needs assessment, and propose to evaluate post-program educational outcomes.
Mitsubishi Tanabe Pharma America is committed to supporting nonprofit organizations that help people living with the diseases that align with our therapeutic areas of focus and mission. Mitsubishi Tanabe Pharma America looks to support programs that directly support care, education, awareness, advocacy, and access.
Mitsubishi Tanabe Pharma America will consider charitable contributions to not-for-profit organizations or institutions whose missions include improving patient care, supporting charitable causes, events, and patient outreach programs. Submissions should align with Mitsubishi Tanabe Pharma America’s therapeutic areas of focus and mission.
Mitsubishi Tanabe Pharma America (MTPA) is committed to supporting Investigator Initiated Trials (IITs) that are intended to foster the advancement of scientific and clinical knowledge and improve patient care. Our IITs Program has been created to provide support for Investigator-Initiated clinical research or Health Economics Outcome Independent Research that illustrates the potential to foster knowledge and understanding of MTPA’s product(s).
Applications for IITs are not being accepted in 2022. We will update this web page once the new submission period is open.